Third, activation of the IL-23/IL-17 pathway was the main manifestation of bone changes in both PsA and AS, however, the anti-citrullinated protein antibody (ACPA) levels were shown to promote bone loss in RA but not in PsA and AS [15,16]. The gene discussed is IL17A; the disease is rheumatoid arthritis.